Q-omics provides the consensus-scored RPL12P35 profile across patient tissues and cancer cell-line models. RPL12P35 expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in PAAD. Among the 18 cancer types available for tumor–normal comparison, RPL12P35 is differentially expressed in 8, with the highest sampling consensus in LIHC. Additionally, RPL12P35 RNA expression shows 10,814 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight PAAD, LIHC, and THYM as cancer lineages where RPL12P35 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RPL12P35 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RPL12P35 survival associations across molecular data types. RPL12P35 RNA expression shows survival associations in the most cancer types (23). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RPL12P35 RNA expression–survival associations across cancer types. High RPL12P35 expression shows unfavorable associations in KIRC and HNSC, but favorable associations in PAAD, READ, SKCM and LUAD. The PAAD Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .017). Together, the overview and detailed table identify PAAD as the clearest survival context for RPL12P35 RNA expression.
This table summarizes RPL12P35 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 8. The strongest signals are observed in LIHC for RNA.
This table ranks reproducible tumor–normal expression differences for RPL12P35. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RPL12P35 shows lower tumor expression in KIRC and KICH and higher tumor expression in LIHC, LUAD, CHOL and KICH. The LIHC box plot shows higher RPL12P35 RNA expression in tumor versus normal tissue (log2 FC = +0.717, t-test p < 0.001).
This table shows molecular features associated with RPL12P35 in patient tissues and cancer cell lines. In patient samples, RPL12P35 shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set.
